论文部分内容阅读
普伐他汀(pravastatin sodium,商品名:Mevalotin,美百乐镇,日本三共公司生产)是最新研制、开发的一种治疗高脂血症新药,该药的作用机制与其它他汀类药物类似,主要是通过竞争性抑制胆固醇合成中的限速酶HMG-CoA还原酶来降低血浆胆固醇水平。许多临床研究表明,普伐他汀降低高脂血症病人的血脂疗效高、安全性好,并能降低心血管事件。本试验主要是观察普伐他汀对中国高脂血症病人的临床疗效和安全性。1.病例选择和方法1.1病例选择 从6个中心共入选了144名高脂血症患者。对于停用降脂药物或开始饮食治疗4周以上,空腹总胆固醇仍
Pravastatin sodium (product name: Mevalotin, Meibaluo Town, Japan’s Sankyo company) is the latest development and development of a new drug for treatment of hyperlipidemia, the drug’s mechanism of action and other statins similar to the main Is to lower plasma cholesterol levels by competitively inhibiting the rate-limiting enzyme HMG-CoA reductase in cholesterol synthesis. Many clinical studies have shown that pravastatin can reduce hyperlipidemia in patients with high blood lipid, high safety, and can reduce cardiovascular events. This experiment is mainly to observe the clinical efficacy and safety of pravastatin in Chinese patients with hyperlipidemia. 1. Case Selection and Methods 1.1 Case Selection A total of 144 patients with hyperlipidemia were enrolled from 6 centers. Fasting total cholesterol remained for more than 4 weeks after discontinuing lipid-lowering drugs or starting dietary therapy